Therapeutic potential of targeting TREM-1 in inflammatory diseases and cancer

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

The triggering receptor expressed on myeloid cells (TREM)-1 is a member of the Ig-like immunoregulatory receptor family and a major amplifier of innate immune responses. TREM-1 has been implicated in the development and perpetuation of a number of inflammatory disorders, and soluble TREM-1 levels are a clinically valuable diagnostic and prognostic biomarker in patients with sepsis and other types of acute and chronic inflammation-associated diseases, easily detectable in biological fluids. High TREM-1 expression in macrophages infiltrating human tumors and increased concentrations of soluble TREM-1 also correlate with aggressive tumor behavior and recurrence and are a relevant independent predictor of poor patient survival. Pharmacological inhibition of TREM-1 has proven effective in preclinical mouse models of infectious and non-infectious inflammatory disorders and malignancies, conferring survival advantages and protecting from organ damage or tumor growth by attenuating inflammatory responses. This review aims at providing a comprehensive overview of the state of the art on TREM-1 research. We review the literature addressing TREM-1 role in the amplification of myeloid cell inflammatory responses at pathologic sites and its relevance in the development, severity, and progression of inflammatory diseases and cancer. Furthermore, we discuss recent advances in the pharmacological use of TREM-1 inhibitors in mouse preclinical models, emphasizing their potential in new strategies for the treatment of acute and chronic inflammatory conditions and for therapeutic intervention in cancer. This information will be of value to investigators in the field of pharmacology, drawing attention to novel therapeutic opportunities to complement current treatment approaches.

Original languageEnglish
Pages (from-to)6209-6233
Number of pages25
JournalCurrent Pharmaceutical Design
Volume22
Issue number41
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

Myeloid Cells
Neoplasms
Therapeutics
Pharmacology
Survival
Innate Immunity
Disease Progression
Sepsis
Biomarkers
Macrophages
Research Personnel
Inflammation
Recurrence

Keywords

  • Cancer
  • Disease models
  • Immunoregulatory receptors
  • Inflammation
  • Inflammatory diseases
  • Innate immune cells
  • Therapy
  • Triggering receptor expressed on myeloid cells

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Therapeutic potential of targeting TREM-1 in inflammatory diseases and cancer. / Bosco, Maria Carla; Raggi, Federica; Varesio, Luigi.

In: Current Pharmaceutical Design, Vol. 22, No. 41, 01.12.2016, p. 6209-6233.

Research output: Contribution to journalReview article

@article{79d44d633feb43dfb375c99c4d395f66,
title = "Therapeutic potential of targeting TREM-1 in inflammatory diseases and cancer",
abstract = "The triggering receptor expressed on myeloid cells (TREM)-1 is a member of the Ig-like immunoregulatory receptor family and a major amplifier of innate immune responses. TREM-1 has been implicated in the development and perpetuation of a number of inflammatory disorders, and soluble TREM-1 levels are a clinically valuable diagnostic and prognostic biomarker in patients with sepsis and other types of acute and chronic inflammation-associated diseases, easily detectable in biological fluids. High TREM-1 expression in macrophages infiltrating human tumors and increased concentrations of soluble TREM-1 also correlate with aggressive tumor behavior and recurrence and are a relevant independent predictor of poor patient survival. Pharmacological inhibition of TREM-1 has proven effective in preclinical mouse models of infectious and non-infectious inflammatory disorders and malignancies, conferring survival advantages and protecting from organ damage or tumor growth by attenuating inflammatory responses. This review aims at providing a comprehensive overview of the state of the art on TREM-1 research. We review the literature addressing TREM-1 role in the amplification of myeloid cell inflammatory responses at pathologic sites and its relevance in the development, severity, and progression of inflammatory diseases and cancer. Furthermore, we discuss recent advances in the pharmacological use of TREM-1 inhibitors in mouse preclinical models, emphasizing their potential in new strategies for the treatment of acute and chronic inflammatory conditions and for therapeutic intervention in cancer. This information will be of value to investigators in the field of pharmacology, drawing attention to novel therapeutic opportunities to complement current treatment approaches.",
keywords = "Cancer, Disease models, Immunoregulatory receptors, Inflammation, Inflammatory diseases, Innate immune cells, Therapy, Triggering receptor expressed on myeloid cells",
author = "Bosco, {Maria Carla} and Federica Raggi and Luigi Varesio",
year = "2016",
month = "12",
day = "1",
doi = "10.2174/1381612822666160826110539",
language = "English",
volume = "22",
pages = "6209--6233",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "41",

}

TY - JOUR

T1 - Therapeutic potential of targeting TREM-1 in inflammatory diseases and cancer

AU - Bosco, Maria Carla

AU - Raggi, Federica

AU - Varesio, Luigi

PY - 2016/12/1

Y1 - 2016/12/1

N2 - The triggering receptor expressed on myeloid cells (TREM)-1 is a member of the Ig-like immunoregulatory receptor family and a major amplifier of innate immune responses. TREM-1 has been implicated in the development and perpetuation of a number of inflammatory disorders, and soluble TREM-1 levels are a clinically valuable diagnostic and prognostic biomarker in patients with sepsis and other types of acute and chronic inflammation-associated diseases, easily detectable in biological fluids. High TREM-1 expression in macrophages infiltrating human tumors and increased concentrations of soluble TREM-1 also correlate with aggressive tumor behavior and recurrence and are a relevant independent predictor of poor patient survival. Pharmacological inhibition of TREM-1 has proven effective in preclinical mouse models of infectious and non-infectious inflammatory disorders and malignancies, conferring survival advantages and protecting from organ damage or tumor growth by attenuating inflammatory responses. This review aims at providing a comprehensive overview of the state of the art on TREM-1 research. We review the literature addressing TREM-1 role in the amplification of myeloid cell inflammatory responses at pathologic sites and its relevance in the development, severity, and progression of inflammatory diseases and cancer. Furthermore, we discuss recent advances in the pharmacological use of TREM-1 inhibitors in mouse preclinical models, emphasizing their potential in new strategies for the treatment of acute and chronic inflammatory conditions and for therapeutic intervention in cancer. This information will be of value to investigators in the field of pharmacology, drawing attention to novel therapeutic opportunities to complement current treatment approaches.

AB - The triggering receptor expressed on myeloid cells (TREM)-1 is a member of the Ig-like immunoregulatory receptor family and a major amplifier of innate immune responses. TREM-1 has been implicated in the development and perpetuation of a number of inflammatory disorders, and soluble TREM-1 levels are a clinically valuable diagnostic and prognostic biomarker in patients with sepsis and other types of acute and chronic inflammation-associated diseases, easily detectable in biological fluids. High TREM-1 expression in macrophages infiltrating human tumors and increased concentrations of soluble TREM-1 also correlate with aggressive tumor behavior and recurrence and are a relevant independent predictor of poor patient survival. Pharmacological inhibition of TREM-1 has proven effective in preclinical mouse models of infectious and non-infectious inflammatory disorders and malignancies, conferring survival advantages and protecting from organ damage or tumor growth by attenuating inflammatory responses. This review aims at providing a comprehensive overview of the state of the art on TREM-1 research. We review the literature addressing TREM-1 role in the amplification of myeloid cell inflammatory responses at pathologic sites and its relevance in the development, severity, and progression of inflammatory diseases and cancer. Furthermore, we discuss recent advances in the pharmacological use of TREM-1 inhibitors in mouse preclinical models, emphasizing their potential in new strategies for the treatment of acute and chronic inflammatory conditions and for therapeutic intervention in cancer. This information will be of value to investigators in the field of pharmacology, drawing attention to novel therapeutic opportunities to complement current treatment approaches.

KW - Cancer

KW - Disease models

KW - Immunoregulatory receptors

KW - Inflammation

KW - Inflammatory diseases

KW - Innate immune cells

KW - Therapy

KW - Triggering receptor expressed on myeloid cells

UR - http://www.scopus.com/inward/record.url?scp=85009223434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009223434&partnerID=8YFLogxK

U2 - 10.2174/1381612822666160826110539

DO - 10.2174/1381612822666160826110539

M3 - Review article

AN - SCOPUS:85009223434

VL - 22

SP - 6209

EP - 6233

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 41

ER -